師慶紅,秦 迪,趙長(zhǎng)福,張 欣,楊照微,黃麗紅*,何成彥
(吉林大學(xué)中日聯(lián)誼醫(yī)院 1.檢驗(yàn)科;2.老年病科;3.骨科,吉林 長(zhǎng)春130033)
CLC-3 siRNA對(duì)人肺動(dòng)脈平滑肌細(xì)胞增殖及細(xì)胞周期的影響
師慶紅1,秦 迪2,趙長(zhǎng)福3,張 欣2,楊照微1,黃麗紅2*,何成彥1
(吉林大學(xué)中日聯(lián)誼醫(yī)院 1.檢驗(yàn)科;2.老年病科;3.骨科,吉林 長(zhǎng)春130033)
目的探討CLC-3 siRNA對(duì)人肺動(dòng)脈平滑肌細(xì)胞(PASMC)增殖及細(xì)胞周期的影響。方法應(yīng)用脂質(zhì)體3000將CLC-3 siRNA轉(zhuǎn)入PASMC。通過免疫印記法測(cè)定了CLC-3 siRNA干擾后PASMC的CLC-3表達(dá)水平;應(yīng)用臺(tái)盼藍(lán)染色計(jì)數(shù)法計(jì)數(shù)了細(xì)胞增殖;流式細(xì)胞儀測(cè)定了細(xì)胞周期。結(jié)果(1)CLC-3 siRNA可降低PASMC的CLC-3表達(dá);(2)CLC-3 siRNA干擾可顯著抑制PASMC增殖,與空白對(duì)照、陰性對(duì)照 siRNA轉(zhuǎn)染組相比P<0.05;(3)CLC-3 siRNA干擾可顯著減少PASMC的S期細(xì)胞、增加G1期細(xì)胞,與空白對(duì)照、陰性對(duì)照 siRNA轉(zhuǎn)染組相比P<0.05。結(jié)論CLC-3 siRNA干擾PASMC表達(dá)CLC-3,可抑制PASMC的增殖并影響其細(xì)胞周期進(jìn)程。
肺動(dòng)脈高壓;肺動(dòng)脈平滑肌細(xì)胞(PASMC);氯離子通道CLC-3;siRNA
(ChinJLabDiagn,2017,21:2171)
肺動(dòng)脈高壓嚴(yán)重威脅著人類健康[1]。研究證實(shí)肺小動(dòng)脈血管增生是肺動(dòng)脈高壓的主要特征之一,肺動(dòng)脈血管平滑肌細(xì)胞(PASMC)增殖在肺動(dòng)脈高壓的發(fā)生發(fā)展中起關(guān)鍵作用[2]。近年來以其為靶點(diǎn)治療肺動(dòng)脈高壓取得一定進(jìn)展。體內(nèi)多種因素影響心肌及血管平滑肌細(xì)胞的增殖,如細(xì)胞腫脹激活性氯離子通道(Icl.swelling)及其氯通道CLC-3等[3,4]。在本研究中我們應(yīng)用CLC-3 siRNA干擾人PASMC表達(dá)CLC-3蛋白,初步探討了干擾其表達(dá)對(duì)人PASMC增殖及其細(xì)胞周期的影響,為進(jìn)一步深入研究CLC-3在肺動(dòng)脈高壓發(fā)病機(jī)制中的作用及以其為靶點(diǎn)新的治療策略奠定實(shí)驗(yàn)基礎(chǔ)。
1.1人PAMSC的培養(yǎng)
人肺動(dòng)脈平滑肌細(xì)胞(HPAMSC,ScienCell)培養(yǎng)于多聚賴氨酸處理(2 μg/cm2)的培養(yǎng)10 mm培養(yǎng)皿中,培養(yǎng)基為平滑肌細(xì)胞生長(zhǎng)培養(yǎng)基(ScienCell),其中含5%胎牛血清、SMCGS、青霉素、鏈霉素。5%二氧化碳培養(yǎng)箱中,生長(zhǎng)至約90%匯合時(shí)傳代。HPAMSC在5至12代用于本實(shí)驗(yàn)。
1.2CLC-3siRNA轉(zhuǎn)染
CLC-3 siRNA由Origene公司合成,序列為:AGCUACAACAGUAUAACAAGUGCAA,陰性對(duì)照siRNA由Origene公司提供。轉(zhuǎn)染方法:將分別用125 μl無血清SCM稀釋的7.5 μl Lipofectamin 3000 和1 μl CLC-3 siRNA(20 μM)混合,室溫孵育15 min,加入接種1×105HPAMSC 的6孔板中,輕輕混勻,培養(yǎng)48 h后進(jìn)行干擾目的基因表達(dá)的檢測(cè)。
1.3免疫印記法檢測(cè)CLC-3蛋白表達(dá)水平
用細(xì)胞裂解液裂解細(xì)胞(Gengstar),制備細(xì)胞總蛋白,BCA法測(cè)定蛋白含量。經(jīng)10%SDS-PAGE電泳后轉(zhuǎn)膜,封閉過夜后加入CLC-3多克隆抗體(CST,1∶1 000稀釋)、GAPDH多克隆抗體(碧云天,1∶1 000稀釋)室溫孵育2 h,洗膜后加入HRP-羊抗兔IgG(碧云天1∶1 000稀釋)室溫孵育1 h,洗膜后加發(fā)光試劑(ThermoFisher),壓片、顯影、定影后觀察記錄結(jié)果。
1.4細(xì)胞增殖的測(cè)定
轉(zhuǎn)染48 h后,用0.004%EDTA-0.05%胰酶消化細(xì)胞,PBS洗2次,用1%臺(tái)盼藍(lán)染色計(jì)數(shù)活細(xì)胞數(shù),每組計(jì)數(shù)3孔。
1.5細(xì)胞周期測(cè)定
轉(zhuǎn)染48 h后,用0.02%EDTA-0.05%胰酶消化細(xì)胞,PBS洗2次后,用200 μl PBS重懸細(xì)胞,逐滴加入到預(yù)冷的70%乙醇中,4℃保存;24 h后離心,PBS洗3次,加入500 μl含50 mg/ml PI、100 μg/ml RNase A、0.2%Triton X-100的PBS,用流式細(xì)胞儀分析細(xì)胞周期。
1.6統(tǒng)計(jì)學(xué)分析
2.1CLC-3siRNA對(duì)人PAMSC表達(dá)CLC-3蛋白的影響
空白對(duì)照、陰性對(duì)照 siRNA轉(zhuǎn)染及CLC-3 siRNA 轉(zhuǎn)染組細(xì)胞,提取細(xì)胞總蛋白,通過免疫印記法檢測(cè)CLC-3蛋白表達(dá)水平。結(jié)果顯示:與PAMSC空白對(duì)照、陰性對(duì)照 siRNA轉(zhuǎn)染組相比,CLC-3 siRNA組CLC-3表達(dá)水平降低,見圖1。
2.2干擾CLC-3表達(dá)對(duì)人PAMSC增殖及細(xì)胞周期的影響
轉(zhuǎn)染48 h后,收集空白對(duì)照、陰性對(duì)照 siRNA轉(zhuǎn)染及CLC-3 siRNA 轉(zhuǎn)染組細(xì)胞,計(jì)數(shù)每孔活細(xì)胞數(shù)并通過流式細(xì)胞儀進(jìn)行細(xì)胞周期分析。結(jié)果顯示:與空白對(duì)照、陰性對(duì)照 siRNA轉(zhuǎn)染組相比,CLC-3 siRNA組活細(xì)胞數(shù)顯著減少(P<0.05);CLC-3 siRNA組S期細(xì)胞呈減少、G1期細(xì)胞增加,與空白對(duì)照、陰性對(duì)照 siRNA轉(zhuǎn)染組相比,P<0.05,見表1。
表1 CLC-3 siRNA對(duì)人肺動(dòng)脈平滑肌細(xì)胞增殖及細(xì)胞周期的影響
*與空白對(duì)照、陰性對(duì)照 siRNA組相比P<0.05
肺動(dòng)脈高壓是以肺小動(dòng)脈血管痙攣、肺小動(dòng)脈血管增生和重構(gòu)為主要特征的一種疾病。PASMC增殖導(dǎo)致肺小動(dòng)脈增生及重構(gòu),在肺動(dòng)脈高壓病理過程中起關(guān)鍵作用[5]。目前針對(duì)PASMC增殖的藥物如前列腺環(huán)素類似物、內(nèi)皮素受體拮抗劑等在臨床治療肺動(dòng)脈高壓中取得了一定療效[6,7],但療效仍不理想。近年來研究發(fā)現(xiàn)細(xì)胞腫脹激活性氯離子通道(Icl.swelling)及其通道基因CLC-3在高血壓、心肌缺血/再灌注、心肌肥厚和心力衰竭中發(fā)揮重要作用[8,9]。氯離子通道阻滯劑DIDS、DCPIB等可影響PASMC 的增殖,為開發(fā)肺動(dòng)脈高壓治療策略指出了新的方向。在本研究中我們應(yīng)用CLC-3 siRNA干擾人PASMC表達(dá)CLC-3蛋白,初步觀察到干擾CLC-3表達(dá)不僅可抑制人PASMC細(xì)胞增殖,而且也影響其細(xì)胞周期進(jìn)程,使部分細(xì)胞阻滯在G1期,進(jìn)入S期細(xì)胞顯著減少。本研究結(jié)果提示我們:CLC-3是研究PASMC增殖的較理想靶點(diǎn),干擾CLC-3表達(dá)可影響PASMC細(xì)胞的 G1/S期轉(zhuǎn)換。本研究為深入探討CLC-3與肺動(dòng)脈高壓相關(guān)性及CLC-3影響PASMC細(xì)胞增殖的機(jī)制奠定了實(shí)驗(yàn)基礎(chǔ)。
[1]Hong David.肺動(dòng)脈高壓所致右心衰竭機(jī)制與治療[J].中國高血壓雜志,2012,20(7):604.
[2]張凌云,高安寶.肺動(dòng)脈平滑肌細(xì)胞與低氧性肺血管重塑形成機(jī)制[J].中國動(dòng)脈硬化雜志,2013,21(2):177.
[3]Xiong D,Heyman N,Airey J,et al.Cardiac-specific,inducible CLC-3 gene deletion eliminates native volume-sensitive chloride channels and produces myocardial hypertrophy in adult mince[J].J Mol Cell Cardiol,2010,48:211.
[4]Chu X,Filali M,Santic B,et al.A critical role for chloride channel-3 (CLC-3) in smooth muscle cell activation and neointima formation[J].Arterioscler Tbromb Vasc Biol,2011,31:345.
[5]Archer SL,Weir EK,Wikins MR,et al.Basic science of pulmonary arterial hypertension for clinicians:new concepts and experimental therapies[J].Circulation,2010,121:2045.
[6]梁富翔,宋 兵,祁 泉,等.內(nèi)皮素受體拮抗劑治療肺動(dòng)脈高壓療效和耐受性的網(wǎng)狀Meta分析[J].中國循證心血管醫(yī)學(xué)雜志,2014,6(7):663.
[7]何建國,楊 濤.肺動(dòng)脈高壓治療新視野[J].中國循環(huán)雜志,2014,29(10):761.
[8]Large WA,Wang Q.Characteristics and physiological role of the Ca2+-activated Cl-conductance in smooth muscle[J].Am J Physiol Cell Physiol,1996,271:C435.
[9]Liang W,Ray JB,He JZ,et al.Regulation of proliferation and membrane potential by chloride currents in rat pulmonary artery smooth muscle cells[J].Hypertension,2009,54:286.
CLC-3siRNAeffectsonHumanPulmonaryArterySmoothMuscleCellsProliferationandcellcycles
SHIQing-hong,QINDi,ZHAOChang-fu,etal.
(China-JapanUnionHospitalofJilinUniversity,Changchun130033,China)
ObjectiveTo evaluate the effects of CLC-3 siRNA on the proliferation and cell cycles of PASMC.MethodsWe transfect CLC-3 siRNA into PASMC by Lipofectamine 3000 reagent.The expression of CLC-3 protein in PASMC is detected by western blotting after CLC-3 siRNA transfection.The cell proliferation of PASMC is counting by trypan blue staining and the cell cycle of PASMC is analyzed by flow cytometry.Results(1)CLC-3 siRNA can reduce the expression of CLC-3 protein in PASMC.(2)CLC-3 siRNA interference can significantly decrease the proliferation of PASMC,compare to blank control,negative siRNA,P<0.05.(3)CLC-3 siRNA interference can significantly reduce the S phase PASMCs and increase G1 phase PASMCs,compare to blank control,negative siRNA ,P<0.05.ConclusionCLC-3 siRNA can interfere the CLC-3 expression in PASMC,and can decrease the proliferation of PASMC and affect the process of PASMC cell cycle.
Pulmonary hepertension;Pulmonary artery smooth muscel cells(PASMC);Chloride channel CLC-3;siRNA
國家自然基金項(xiàng)目(81572082);吉林省科技廳資助(2015010153JC,20140311092YY)
*通訊作者
1007-4287(2017)12-2171-03
R543.2
A
2017-03-14)